TNFSF9 and Miyoshi myopathy: Furthermore, it has been reported that CD137L expression decreased in patients who achieved good responses (partial response [PR] or better) after treatment [52], suggesting that CD137L may be involved in the development of MM and could contribute to therapy resistance.